老年膀胱癌患者自适应大分割放疗的临床结局
回顾性分析两中心1990—2021年122例>75岁非转移性肌层浸润性膀胱癌患者,接受经尿道膀胱肿瘤切除术后同步放化疗(铂盐和5-氟尿嘧啶)及自适应双分次分段大分割放疗;3年总生存率61.7%、5年51.2%,≥3级急性和晚期毒性均<5%。
要点
- 83.5%患者完成放化疗,3年OS率61.7%、5年OS率51.2%。
- 适合根治性膀胱切除者中77例(91.7%)达完全组织学缓解,保膀胱率90.5%。
- ≥3级急性和晚期毒性均<5%;完成放疗和同步化疗与更好OS及肿瘤特异性生存显著相关。
核心结论
- 双分次分段大分割放疗联合同步化疗方案似乎耐受良好且有效。
- 三联治疗似乎是适合根治性手术的老年患者的治愈性选择,与姑息治疗相比,并可能有助于改善这些患者的生存。
研究设计与样本
- 回顾性研究,纳入1990至2021年法国巴黎Saint Louis医院和欧洲Georges Pompidou医院两机构中年龄>75岁、非转移性肌层浸润性膀胱癌、适合或不适合根治性膀胱切除术并接受经尿道膀胱肿瘤切除术后同步放化疗(铂盐和5-氟尿嘧啶)的患者,共122例。
- 放疗为自适应双分次分段大分割放疗;急性毒性按不良事件通用术语标准5.0版报告,晚期毒性按放射治疗肿瘤学组/欧洲癌症研究与治疗组织晚期放射损伤评分方案报告。
- 主要终点为总生存期,次要终点包括其他生存结局和安全性;中位(范围)随访51.1(0.5-210.8)个月。
主要发现
- 83.5%的患者完成放化疗。
- 3年总生存率为61.7%,5年总生存率为51.2%。
- 多因素分析中,完成放疗和同步化疗与更好的总生存期和肿瘤特异性生存期显著相关。
- 适合根治性膀胱切除术的患者中,77例(91.7%)经放化疗达到完全组织学缓解,保膀胱率为90.5%。
- 急性和晚期≥3级毒性均<5%。
临床怎么用
- 作者认为双分次分段大分割放疗联合同步化疗方案似乎耐受良好且有效。
- 作者认为三联治疗似乎是适合根治性手术的老年患者的治愈性选择,与姑息治疗相比,并可能有助于改善这些患者的生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the feasibility, efficacy, and safety of trimodal therapy (TMT) using a bifractionated split-course hypofractionated radiotherapy (RT) for non-metastatic muscle-invasive bladder cancer (MIBC) in elderly patients. PATIENTS AND METHODS: We retrospectively reviewed the characteristics and outcomes of patients aged >75 years with non-metastatic MIBC suitable or not for radical cystectomy (RC) and treated with transurethral resection of bladder tumour followed by concomitant radio-chemotherapy (platinum salt and 5-fluorouracil) at two institutions (Saint Louis Hospital, Paris, France and European Georges Pompidou Hospital, Paris, France) between 1990 and 2021. RT consisted of an adapted bifractionated split-course hypofractionated RT. Acute toxicities were reported according to Common Terminology Criteria for Adverse Events version 5.0 and late toxicities were reported according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer late radiation morbidity scoring schema. The primary end-point was overall survival (OS). Secondary end-points included other survivals outcomes and safety. RESULTS: A total of 122 patients were identified, with a median (range) follow-up of 51.1 (0.5-210.8) months. In all, 83.5% of patients completed radio-chemotherapy. The OS rate was 61.7% at 3 years and 51.2% at 5 years. In multivariate analysis, the completion of RT and concomitant chemotherapy were significantly associated with better OS and cancer-specific survival. For patients fit for RC, a complete histological response was achieved for 77 patients (91.7%) with radio-chemotherapy and the bladder conservation rate was 90.5%. Acute and late Grade ≥3 toxicities were <5%. CONCLUSION: Bifractionated split-course hypofractionated RT with concomitant chemotherapy regimen appears to be well-tolerated and effective. Trimodal treatment seems to be a curative option for elderly patients unfit for radical surgery compared with palliative care and may contribute to improved survival in these patients.
引用
- Mignot F, Fabiano E, Xylinas E, et al. Clinical outcomes of adapted hypofractionated radiotherapy for bladder cancer in elderly patients. BJU Int. 2023. PMID: 36745012. doi:10.1111/bju.15983
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。